Table 2.

Risk of Cervical Intraepithelial Neoplasia Grade 2 or Greater (CIN-2+) After 3 or 5 Years of Follow-up, and Its Relationship With Oncogenic Human Papillomavirus Detection at Baseline in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Women With a Normal Baseline Pap Result^a

Characteristic	3 y HR (95% CI)	P Value	5 y HR (95% CI)	P Value
HPV status
OncHPV negative	Reference		Reference
OncHPV positive	6.4 (3.1–12.9)	<.0001	5.3 (2.9–9.4)	<.0001
Year of enrollment
1994–1995	Reference		Reference
2001–2002	1.1 (.5–2.3)	.8	1.0 (.5–1.8)	.9
CD4 count (HIV+)
HIV−	Reference		Reference
>500 cells/µL	3.2 (1.1–9.4)	.04	2.3 (1.0–5.1)	.05
350–500 cells/µL	2.2 (.6–7.4)	.2	1.8 (.7–4.5)	.2
<350 cells/µL	4.9 (1.6–15.4)	.01	3.0 (1.3–7.1)	.01
Age at baseline (continuous)	0.9 (.9–1.0)	.005	0.9 (.9–1.0)	.003
Race
Black	Reference		Reference
Hispanic	1.6 (.7–3.4)	.3	1.1 (.6–2.2)	.7
White	0.2 (.0–1.6)	.1	0.3 (.1–1.0)	.1
Other	2.3 (.6–8.2)	.2	2.1 (.7–6.1)	.2
Smoking
Never	Reference		Reference
Past	1.7 (.6–4.4)	.3	1.2 (.5–3.0)	.7
Current	1.1 (.5–2.5)	.8	1.5 (.8–2.9)	.2
Lifetime No. of male sexual partners
<5	Reference		Reference
5–9	1.5 (.5–4.4)	.4	1.2 (.5–2.8)	.7
10–49	2.0 (.7–5.4)	.2	1.6 (.7–3.6)	.2
≥50	1.4 (.4–4.6)	.6	0.9 (.3–2.3)	.8

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, hazard ratio; OncHPV; oncogenic human papillomavirus.

^a In secondary data analysis, we observed similar results when incorporating nonparametric splines in the Cox model; that is, the average HRs after 3 or 5 years of follow-up, as measured using the area under the curve, were similar to those presented in the tables, and no statistically significant departures from proportionality were detected.